The same group further designed dual-targeted and glutathione (GSH)-responsive nanoparticles (SSBPEI-DOX@siRNAs/iRGD-PEG-HA) for co-delivery of DOX and siRNA cocktails (survivin siRNA, Bcl-2 siRNA, and ABCG2 siRNA) to ovarian cancer stem cells. Here, BIRC5 is linked to ovarian carcinoma.